H.R. 1414 · 119th Congress

Cameron’s Law

Introduced on Feb 18, 2025 by Josh Gottheimer (D-NJ-5). 19 cosponsors, 11 of them from another party. Latest action (Feb 18, 2025): Referred to the House Committee on Ways and Means.

Stage
Introduced
Introduced
Feb 18, 2025
Cosponsors
19
11 from the other party
Policy area
Taxation
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit.

Summary

By the Congressional Research Service (Introduced in House, Feb 18, 2025). Public domain.

Cameron's Law

This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions.

As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Josh GottheimerD-NJ-5Sponsor

Democrats · 8

Republicans · 11

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 18, 2025Introduced in House
  2. Feb 18, 2025Introduced in House
  3. Feb 18, 2025 · HouseReferred to the House Committee on Ways and Means.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. Travere Therapeutics12 reports
    $1.1M reported (all issues)Federal contractor: TRAVERE THERAPEUTICS, INC.$323.9K in contracts, FY2026AI match · 100%
  2. SOLENO THERAPEUTICS, INC.8 reports
    $420K reported (all issues)
  3. ACADIA PHARMACEUTICALS6 reports
    $3.6M reported (all issues)
  4. AstraZeneca Pharmaceuticals LP6 reports
    $9.1M reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  5. HealthCare Institute of New Jersey6 reports
    $283.8K reported (all issues)
  6. IONIS PHARMACEUTICALS, INC.6 reports
    $760K reported (all issues)
  7. PTC THERAPEUTICS, INC.6 reports
    $1.2M reported (all issues)
  8. RARE DISEASE COMPANY COALITION5 reports
    $350K reported (all issues)
  9. VERTEX PHARMACEUTICALS INCORPORATED5 reports
    $5.7M reported (all issues)
  10. ALKERMES, INC.4 reports
    $4M reported (all issues)
  11. Astria Therapeutics, Inc.4 reports
    $160K reported (all issues)
  12. BRIDGEBIO PHARMA INC.3 reports
    $910K reported (all issues)
  13. ModernaTX, Inc.3 reports
    $90K reported (all issues)Federal contractor: MODERNATX, INC.AI match · 96%
  14. Black Women's Health Imperative2 reports
    $40K reported (all issues)
  15. HARMONY BIOSCIENCES, LLC2 reports
    $360K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  16. National Organization for Rare Disorders, Inc. (NORD)2 reports
    $110K reported (all issues)Federal contractor: THE NATIONAL ORGANIZATION FOR RARE DISORDERS INCAI match · 100%
  17. EVERYLIFE FOUNDATION FOR RARE DISEASES1 report
    $40K reported (all issues)
  18. Inozyme Pharma1 report
    $20K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 8, 2026 · loaded Oct 8, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.